Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era |
Chung-Feng Huang1,2,3, Manar Hijaze Awad4, Meital Gal-Tanamy4, Ming-Lung Yu1.2.5 |
1Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan 2Faculty of Internal Medicine and Hepatitis Research Center, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 3Ph.D. Program in Translational Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, and Academia Sinica, Taiwan 4Molecular Virology Lab, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel 5School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwan |
|
Received: June 24, 2024 Accepted: June 29, 2024 *Chung-Feng Huang and Manar Hijaze Awad contributed equally to this work. |
|
|
|